Discipline of Pharmacology, School of Medical Sciences, University of Adelaide, Adelaide, SA 5005, Australia.
Br J Clin Pharmacol. 2012 Nov;74(5):835-41. doi: 10.1111/j.1365-2125.2012.04256.x.
Management of pain in opioid dependent individuals is problematic due to numerous issues including cross-tolerance to opioids. Hence there is a need to find alternative analgesics to classical opioids and tramadol is potentially one such alternative. Methadone inhibits CYP2D6 in vivo and in vitro. We aimed to investigate the effect of methadone on the pathways of tramadol metabolism: O-demethylation (CYP2D6) to the opioid-active metabolite M1 and N-demethylation (CYP3A4) to M2 in subjects maintained on methadone or buprenorphine as a control.
Compared with subjects on buprenorphine, methadone reduced the clearance of tramadol to active O-desmethyl-tramadol (M1) but had no effect on N-desmethyltramadol (M2) formation. Similar to other analgesics whose active metabolites are formed by CYP2D6 such as codeine, reduced formation of O-desmethyltramadol (M1) is likely to result in reduced analgesia for subjects maintained on methadone. Hence alternative analgesics whose metabolism is independent of CYP2D6 should be utilized in this patient population.
To compare the O- (CYP2D6 mediated) and N- (CYP3A4 mediated) demethylation metabolism of tramadol between methadone and buprenorphine maintained CYP2D6 extensive metabolizer subjects. METHODS Nine methadone and seven buprenorphine maintained subjects received a single 100 mg dose of tramadol hydrochloride. Blood was collected at 4 h and assayed for tramadol, methadone, buprenorphine and norbuprenorphine (where appropriate) and all urine over 4 h was assayed for tramadol and its M1 and M2 metabolites.
The urinary metabolic ratio [median (range)] for O-demethylation (M1) was significantly lower (P= 0.0002, probability score 1.0) in the subjects taking methadone [0.071 (0.012-0.103)] compared with those taking buprenorphine [0.192 (0.108-0.392)], but there was no significant difference (P= 0.21, probability score 0.69) in N-demethylation (M2). The percentage of dose [median (range)] recovered as M1 was significantly lower in subjects taking methadone compared with buprenorphine (0.069 (0.044-0.093) and 0.126 (0.069-0.187), respectively, P= 0.04, probability score 0.19), M2 was significantly higher in subjects taking methadone compared with buprenorphine (0.048 (0.033-0.085) and 0.033 (0.014-0.049), respectively, P= 0.04, probability score 0.81). Tramadol was similar (0.901 (0.635-1.30) and 0.685 (0.347-1.04), respectively, P= 0.35, probability score 0.65).
Methadone inhibited the CYP2D6-mediated metabolism of tramadol to M1. Hence, as the degree of opioid analgesia is largely dependent on M1 formation, methadone maintenance patients may not receive adequate analgesia from oral tramadol.
由于包括阿片类药物交叉耐受在内的许多问题,阿片类药物依赖个体的疼痛管理存在问题。因此,需要寻找替代经典阿片类药物的镇痛剂,曲马多可能是一种替代药物。美沙酮在体内和体外抑制 CYP2D6。我们旨在研究美沙酮对曲马多代谢途径的影响:O-去甲基化(CYP2D6)转化为阿片类活性代谢物 M1 和 N-去甲基化(CYP3A4)转化为 M2,在接受美沙酮或丁丙诺啡维持治疗的受试者中。
与接受丁丙诺啡治疗的受试者相比,美沙酮降低了曲马多向活性 O-去甲基曲马多(M1)的清除率,但对 N-去甲基曲马多(M2)的形成没有影响。与其他阿片类药物类似,其活性代谢物由 CYP2D6 形成,如可待因,减少 O-去甲基曲马多(M1)的形成可能导致接受美沙酮维持治疗的患者的镇痛作用降低。因此,应该在这一患者群体中使用代谢不依赖 CYP2D6 的替代镇痛剂。
比较美沙酮和丁丙诺啡维持的 CYP2D6 广泛代谢者受试者中美沙酮和丁丙诺啡对曲马多的 O-(CYP2D6 介导)和 N-(CYP3A4 介导)去甲基化代谢。方法:9 名美沙酮和 7 名丁丙诺啡维持受试者接受单次 100mg 盐酸曲马多剂量。在 4 小时时采集血液,并测定曲马多、美沙酮、丁丙诺啡和去甲丁丙诺啡(如适用),并测定 4 小时内的所有尿液中的曲马多及其 M1 和 M2 代谢物。
接受美沙酮治疗的受试者的 O-去甲基化(M1)代谢比(中位数(范围))[0.071(0.012-0.103)]显著低于接受丁丙诺啡治疗的受试者[0.192(0.108-0.392)],(P=0.0002,概率评分 1.0),但 N-去甲基化(M2)无显著差异(P=0.21,概率评分 0.69)。接受美沙酮治疗的受试者的 M1 恢复剂量百分比[中位数(范围)]明显低于接受丁丙诺啡治疗的受试者[0.069(0.044-0.093)和 0.126(0.069-0.187),分别,P=0.04,概率评分 0.19],M2 明显高于接受美沙酮治疗的受试者与接受丁丙诺啡治疗的受试者[0.048(0.033-0.085)和 0.033(0.014-0.049),分别,P=0.04,概率评分 0.81]。曲马多相似(0.901(0.635-1.30)和 0.685(0.347-1.04),分别,P=0.35,概率评分 0.65)。
美沙酮抑制了曲马多向 M1 的 CYP2D6 介导代谢。因此,由于阿片类药物镇痛的程度在很大程度上取决于 M1 的形成,美沙酮维持治疗的患者可能无法从口服曲马多中获得足够的镇痛效果。